Daniel J. Lippis, serving as Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences Corp (NASDAQ: EW), executed a series of stock transactions on June 30, 2026. The executive sold 619 shares of the company’s common stock, generating a total value of $56,576. Individual share prices for this transaction ranged from $91.185 to $91.650. This sale was conducted pursuant to a Rule 10b5-1 trading plan that Mr. Lippis adopted on February 13, 2026.
Mr. Lippis also acquired 619 shares of common stock through the exercise of employee stock options on the same day. These shares were acquired at a price of $72.68 per share, totaling $44,988. The options had an exercise date of May 7, 2021, and are set to expire on May 6, 2027. Following these transactions, Mr. Lippis directly owns 40,410.9103 shares of Edwards Lifesciences common stock.
The timing of these transactions is notable as Edwards Lifesciences stock is trading near its 52-week high of $92.88. According to InvestingPro data, the stock is currently overvalued relative to its Fair Value. The $52.3 billion medical device company trades at a P/E ratio of 48.91.
In other recent news, Edwards Lifesciences presented clinical trial data at the New York Valves 2026 conference. The data from the PROGRESS trial focused on transcatheter aortic valve replacement for patients with moderate aortic stenosis, revealing that over 95% of participants were symptomatic. Meanwhile, a proposed National Coverage Decision memo by the U.S. government, which includes coverage for asymptomatic severe aortic stenosis and other relaxed restrictions, has been positively received by analysts, suggesting potential benefits for Edwards Lifesciences.
Following this proposal, Leerink reiterated its Market Perform rating on the company’s stock, maintaining a price target of $87. TD Cowen also raised its price target to $104, highlighting Edwards Lifesciences as its top pick among large-cap medical technology companies, expecting market share gains in TAVR. Additionally, Edwards Lifesciences announced the appointment of Theodora Mistras as the new chief financial officer, effective at the end of May. She will succeed Scott Ullem, who has been with the company since 2014.
These developments indicate significant activity and potential growth for Edwards Lifesciences in the medical technology sector.